Literature DB >> 31253177

Evolving neoantigen profiles in colorectal cancers with DNA repair defects.

Giuseppe Rospo1, Annalisa Lorenzato1,2, Nabil Amirouchene-Angelozzi3, Alessandro Magrì1,2, Carlotta Cancelliere1, Giorgio Corti1, Carola Negrino1,2, Vito Amodio1,2, Monica Montone1, Alice Bartolini1, Ludovic Barault1,2, Luca Novara1, Claudio Isella1, Enzo Medico1,2, Andrea Bertotti1,2, Livio Trusolino1,2, Giovanni Germano1,2, Federica Di Nicolantonio1,2, Alberto Bardelli4,5.   

Abstract

BACKGROUND: Neoantigens that arise as a consequence of tumor-specific mutations can be recognized by T lymphocytes leading to effective immune surveillance. In colorectal cancer (CRC) and other tumor types, a high number of neoantigens is associated with patient response to immune therapies. The molecular processes governing the generation of neoantigens and their turnover in cancer cells are poorly understood. We exploited CRC as a model system to understand how alterations in DNA repair pathways modulate neoantigen profiles over time.
METHODS: We performed whole exome sequencing (WES) and RNA sequencing (RNAseq) in CRC cell lines, in vitro and in vivo, and in CRC patient-derived xenografts (PDXs) to track longitudinally genomic profiles, clonal evolution, mutational signatures, and predicted neoantigens.
RESULTS: The majority of CRC models showed remarkably stable mutational and neoantigen profiles; however, those carrying defects in DNA repair genes continuously diversified. Rapidly evolving and evolutionary stable CRCs displayed characteristic genomic signatures and transcriptional profiles. Downregulation of molecules implicated in antigen presentation occurred selectively in highly mutated and rapidly evolving CRC.
CONCLUSIONS: These results indicate that CRCs carrying alterations in DNA repair pathways display dynamic neoantigen patterns that fluctuate over time. We define CRC subsets characterized by slow and fast evolvability and link this phenotype to downregulation of antigen-presenting cellular mechanisms. Longitudinal monitoring of the neoantigen landscape could be relevant in the context of precision medicine.

Entities:  

Keywords:  Colorectal cancer; DNA repair; Immune response; Mutational signature; Neoantigen

Mesh:

Substances:

Year:  2019        PMID: 31253177      PMCID: PMC6599263          DOI: 10.1186/s13073-019-0654-6

Source DB:  PubMed          Journal:  Genome Med        ISSN: 1756-994X            Impact factor:   11.117


  53 in total

1.  Gapped sequence alignment using artificial neural networks: application to the MHC class I system.

Authors:  Massimo Andreatta; Morten Nielsen
Journal:  Bioinformatics       Date:  2015-10-29       Impact factor: 6.937

2.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Authors:  Giulia Siravegna; Benedetta Mussolin; Michela Buscarino; Giorgio Corti; Andrea Cassingena; Giovanni Crisafulli; Agostino Ponzetti; Chiara Cremolini; Alessio Amatu; Calogero Lauricella; Simona Lamba; Sebastijan Hobor; Antonio Avallone; Emanuele Valtorta; Giuseppe Rospo; Enzo Medico; Valentina Motta; Carlotta Antoniotti; Fabiana Tatangelo; Beatriz Bellosillo; Silvio Veronese; Alfredo Budillon; Clara Montagut; Patrizia Racca; Silvia Marsoni; Alfredo Falcone; Ryan B Corcoran; Federica Di Nicolantonio; Fotios Loupakis; Salvatore Siena; Andrea Sartore-Bianchi; Alberto Bardelli
Journal:  Nat Med       Date:  2015-06-01       Impact factor: 53.440

3.  Stromal contribution to the colorectal cancer transcriptome.

Authors:  Claudio Isella; Andrea Terrasi; Sara Erika Bellomo; Consalvo Petti; Giovanni Galatola; Andrea Muratore; Alfredo Mellano; Rebecca Senetta; Adele Cassenti; Cristina Sonetto; Giorgio Inghirami; Livio Trusolino; Zsolt Fekete; Mark De Ridder; Paola Cassoni; Guy Storme; Andrea Bertotti; Enzo Medico
Journal:  Nat Genet       Date:  2015-02-23       Impact factor: 38.330

4.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

5.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.

Authors:  Michael I Love; Wolfgang Huber; Simon Anders
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

6.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.

Authors:  Wanjuan Yang; Jorge Soares; Patricia Greninger; Elena J Edelman; Howard Lightfoot; Simon Forbes; Nidhi Bindal; Dave Beare; James A Smith; I Richard Thompson; Sridhar Ramaswamy; P Andrew Futreal; Daniel A Haber; Michael R Stratton; Cyril Benes; Ultan McDermott; Mathew J Garnett
Journal:  Nucleic Acids Res       Date:  2012-11-23       Impact factor: 16.971

7.  Signatures of mutational processes in human cancer.

Authors:  Ludmil B Alexandrov; Serena Nik-Zainal; David C Wedge; Samuel A J R Aparicio; Sam Behjati; Andrew V Biankin; Graham R Bignell; Niccolò Bolli; Ake Borg; Anne-Lise Børresen-Dale; Sandrine Boyault; Birgit Burkhardt; Adam P Butler; Carlos Caldas; Helen R Davies; Christine Desmedt; Roland Eils; Jórunn Erla Eyfjörd; John A Foekens; Mel Greaves; Fumie Hosoda; Barbara Hutter; Tomislav Ilicic; Sandrine Imbeaud; Marcin Imielinski; Marcin Imielinsk; Natalie Jäger; David T W Jones; David Jones; Stian Knappskog; Marcel Kool; Sunil R Lakhani; Carlos López-Otín; Sancha Martin; Nikhil C Munshi; Hiromi Nakamura; Paul A Northcott; Marina Pajic; Elli Papaemmanuil; Angelo Paradiso; John V Pearson; Xose S Puente; Keiran Raine; Manasa Ramakrishna; Andrea L Richardson; Julia Richter; Philip Rosenstiel; Matthias Schlesner; Ton N Schumacher; Paul N Span; Jon W Teague; Yasushi Totoki; Andrew N J Tutt; Rafael Valdés-Mas; Marit M van Buuren; Laura van 't Veer; Anne Vincent-Salomon; Nicola Waddell; Lucy R Yates; Jessica Zucman-Rossi; P Andrew Futreal; Ultan McDermott; Peter Lichter; Matthew Meyerson; Sean M Grimmond; Reiner Siebert; Elías Campo; Tatsuhiro Shibata; Stefan M Pfister; Peter J Campbell; Michael R Stratton
Journal:  Nature       Date:  2013-08-14       Impact factor: 49.962

8.  Patient-derived xenografts undergo mouse-specific tumor evolution.

Authors:  Uri Ben-David; Gavin Ha; Yuen-Yi Tseng; Noah F Greenwald; Coyin Oh; Juliann Shih; James M McFarland; Bang Wong; Jesse S Boehm; Rameen Beroukhim; Todd R Golub
Journal:  Nat Genet       Date:  2017-10-09       Impact factor: 38.330

9.  Mutational Signatures in Cancer (MuSiCa): a web application to implement mutational signatures analysis in cancer samples.

Authors:  Marcos Díaz-Gay; Maria Vila-Casadesús; Sebastià Franch-Expósito; Eva Hernández-Illán; Juan José Lozano; Sergi Castellví-Bel
Journal:  BMC Bioinformatics       Date:  2018-06-14       Impact factor: 3.169

10.  Genetic and transcriptional evolution alters cancer cell line drug response.

Authors:  Uri Ben-David; Benjamin Siranosian; Gavin Ha; Helen Tang; Yaara Oren; Kunihiko Hinohara; Craig A Strathdee; Joshua Dempster; Nicholas J Lyons; Robert Burns; Anwesha Nag; Guillaume Kugener; Beth Cimini; Peter Tsvetkov; Yosef E Maruvka; Ryan O'Rourke; Anthony Garrity; Andrew A Tubelli; Pratiti Bandopadhayay; Aviad Tsherniak; Francisca Vazquez; Bang Wong; Chet Birger; Mahmoud Ghandi; Aaron R Thorner; Joshua A Bittker; Matthew Meyerson; Gad Getz; Rameen Beroukhim; Todd R Golub
Journal:  Nature       Date:  2018-08-08       Impact factor: 49.962

View more
  14 in total

Review 1.  Precision oncology in metastatic colorectal cancer - from biology to medicine.

Authors:  Federica Di Nicolantonio; Pietro Paolo Vitiello; Silvia Marsoni; Salvatore Siena; Josep Tabernero; Livio Trusolino; Rene Bernards; Alberto Bardelli
Journal:  Nat Rev Clin Oncol       Date:  2021-04-16       Impact factor: 66.675

2.  Substitution mutational signatures in whole-genome-sequenced cancers in the UK population.

Authors:  Andrea Degasperi; Xueqing Zou; Tauanne Dias Amarante; Andrea Martinez-Martinez; Gene Ching Chiek Koh; João M L Dias; Laura Heskin; Lucia Chmelova; Giuseppe Rinaldi; Valerie Ya Wen Wang; Arjun S Nanda; Aaron Bernstein; Sophie E Momen; Jamie Young; Daniel Perez-Gil; Yasin Memari; Cherif Badja; Scott Shooter; Jan Czarnecki; Matthew A Brown; Helen R Davies; Serena Nik-Zainal
Journal:  Science       Date:  2022-04-22       Impact factor: 63.714

3.  GNIFdb: a neoantigen intrinsic feature database for glioma.

Authors:  Wendong Li; Ting Sun; Muyang Li; Yufei He; Lin Li; Lu Wang; Haoyu Wang; Jing Li; Hao Wen; Yong Liu; Yifan Chen; Yubo Fan; Beibei Xin; Jing Zhang
Journal:  Database (Oxford)       Date:  2022-02-12       Impact factor: 4.462

4.  Hypoxia increases mutational load of breast cancer cells through frameshift mutations.

Authors:  Goutham Hassan Venkatesh; Pamela Bravo; Walid Shaaban Moustafa Elsayed; Francis Amirtharaj; Bartosz Wojtas; Raefa Abou Khouzam; Husam Hussein Nawafleh; Sandeep Mallya; Kapaettu Satyamoorthy; Philippe Dessen; Filippo Rosselli; Jerome Thiery; Salem Chouaib
Journal:  Oncoimmunology       Date:  2020-04-16       Impact factor: 8.110

Review 5.  Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response.

Authors:  Elaine R Mardis
Journal:  Genome Med       Date:  2019-11-20       Impact factor: 11.117

6.  CPNE1 Enhances Colorectal Cancer Cell Growth, Glycolysis, and Drug Resistance Through Regulating the AKT-GLUT1/HK2 Pathway.

Authors:  Yuexia Wang; Shengli Pan; Xinhong He; Ying Wang; Haozhe Huang; Junxiang Chen; Yuhao Zhang; Zhijin Zhang; Xianju Qin
Journal:  Onco Targets Ther       Date:  2021-01-27       Impact factor: 4.147

7.  Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer.

Authors:  Luca Lazzari; Giorgio Corti; Gabriele Picco; Claudio Isella; Monica Montone; Pamela Arcella; Erika Durinikova; Eugenia R Zanella; Luca Novara; Fabiane Barbosa; Andrea Cassingena; Carlotta Cancelliere; Enzo Medico; Andrea Sartore-Bianchi; Salvatore Siena; Mathew J Garnett; Andrea Bertotti; Livio Trusolino; Federica Di Nicolantonio; Michael Linnebacher; Alberto Bardelli; Sabrina Arena
Journal:  Clin Cancer Res       Date:  2019-08-02       Impact factor: 12.531

8.  neoDL: a novel neoantigen intrinsic feature-based deep learning model identifies IDH wild-type glioblastomas with the longest survival.

Authors:  Ting Sun; Yufei He; Wendong Li; Guang Liu; Lin Li; Lu Wang; Zixuan Xiao; Xiaohan Han; Hao Wen; Yong Liu; Yifan Chen; Haoyu Wang; Jing Li; Yubo Fan; Wei Zhang; Jing Zhang
Journal:  BMC Bioinformatics       Date:  2021-07-23       Impact factor: 3.169

9.  Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.

Authors:  Milene Peterson; Sierra Nicole Murphy; John Lainson; Jian Zhang; Luhui Shen; Chris W Diehnelt; Stephen Albert Johnston
Journal:  BMC Immunol       Date:  2020-05-05       Impact factor: 3.615

10.  Complete response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT mutations and high tumour mutational burden.

Authors:  João D Barros-Silva; Andrew D Beggs; Joanne D Stockton; Louise Tee; Celina Whalley; Jonathan James; Mark Dilworth; Rachel Wheat; Thomas Nieto; Ian Geh
Journal:  Radiat Oncol       Date:  2021-07-13       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.